Last edition
News about "Memorial Sloan Kettering Cancer Center"
Actinium Pharmaceuticals has entered a research collaboration with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation-agnostic mechanism in AML through targeted therapy combinations and patient-derived models.
Memorial Sloan Kettering Cancer Center | 20/03/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members